Skip links

Working Group 505/06

Clinical Treatment Recommendation

No of members

WG Leader



Prof Sebastian BRANDNER

Clinical Research

01 Objectives

To improve patient outcomes through personalised medicine research. Relevant to RCO5, RCO4, RCO3

02 Tasks

T5.1 Improve the state-of-the-art and good practices in RT optimalisation; T5.2 Establish network of clinicians leading investigator-initiated trial in brain tumours; T5.3 WG3 meetings

03 Activities

Involved in all MC and WG5 meetings including organising a WG4/WG5-focused conference, contribute to annual and final reports, the final year conference; 2 peer reviewed joint publications, contribute to dissemination, exploitation, training schools.


M5.1: Mid-term report in month 25; M5.2: WG4/WG5 conference in month 34.


CLINICAL TREATMENT RECOMMENDATIONS (Theme-5) This theme aims to develop new therapeutic approaches in radiotherapy (RT). Novel pathological grading strategies will be exploited by combining radiomics and multimodal -omics techniques for RT. Specifically, to reduce treatment for less-aggressive brain tumours, it is very important to distinguish between low-risk of growth (LRG) and high-risk of growth (HRG) patients. For instance, the “Wait and See” following-up strategy can be directly applied to LRG patients.
Among the HRG patients, 1) high-grade patients may need immediate surgery and/or RT; 2) low-grade with a low risk of recurrence (LRR) patients may just need routine “Wait and See” following up; 3) low-grade with a high risk of recurrence (HRR) patients may need aggressive RT treatment and frequent following up. Combining radiomics with blood-based biomarkers and genotypic patterns supported by AI/ML has the potential to provide more precision and robust grading, i.e., distinguishing LRG, HRG, LRR and HRR, for personalised treatment. In addition, the brain metastasis prognosis model has a high chance to be applied in RT clinical practice.
Moreover, the new TGM will be applied to optimize RT, e.g., optimize the shape of the radiation beam as well as dose painting to significantly increase the number of tumour cells killed during RT treatment. Furthermore, it is reported that novel SSRT has the potential to change clinical practice although its application is still in its infancy. Thus, this Action aims to develop clinically reasonable guidelines and protocol for accurate SSRT treatment based on patient stratification and prognostic biomarkers.